Skip to main content
. 2016 Mar 15;4:12. doi: 10.1186/s40425-016-0116-2

Fig. 2.

Fig. 2

Lesion level time to response (Kaplan-Meier survival curves) for talimogene laherparepvec for injected, all uninjected, uninjected non-visceral, or visceral lesions in the phase II clinical trial of talimogene laherparepvec in patients with stage IIIC or IV melanoma. Safety analysis set consisted of patients who received at least one dose of study therapy